Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 13 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 11384337

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  2. US 11382922

    Aqueous oral pharmaceutical suspension compositions

    ReveraGen BioPharma, Inc. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  3. US 11376273

    Modulation of factor 11 expression

    Ionis Pharmaceuticals, Inc. · Granted Jul 5, 2022 · Expires Jun 30, 2042

    granted
  4. US 11365416

    Modulators of EZH2 expression

    Ionis Pharmaceuticals, Inc. · Granted Jun 21, 2022 · Expires Jun 16, 2042

    granted
  5. US 11357841

    Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof

    Iovance Biotherapeutics, Inc. · Granted Jun 14, 2022 · Expires Jun 9, 2042

    granted
  6. US 11351190

    Composition for treating tissue lesions

    ORGANES TISSUS REGENERATION REPARATION REMPLACEMENT—OTR3 · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted
  7. US 11352402

    Interleukin-4 receptor-binding fusion proteins and uses thereof

    Medicenna Therapeutics Inc. · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted
  8. US 11352639

    Gene therapy based on vector VTVAF17

    OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTJU “ALLEL TSENTR INNOVATSIONNYKH BIOTEKHNOLOGY” · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted
  9. US 11351118

    Methods for ameliorating infusion reactions

    ARBUTUS BIOPHARMA CORPORATION · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted
  10. US 11345733

    Colon and pancreas cancer specific antigens and antibodies

    PRECISION BIOLOGICS, INC. · Granted May 31, 2022 · Expires May 26, 2042

    granted
  11. US 11345904

    Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted May 31, 2022 · Expires May 26, 2042

    granted
  12. US 11345894

    Cellular seeding and co-culture of a three dimensional fibroblast construct

    United States Government as represented by the Department of Veterans Affairs · Granted May 31, 2022 · Expires May 26, 2042

    granted
  13. US 11344577

    Car+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA

    The Board of Regents of the University of Texas System · Granted May 31, 2022 · Expires May 26, 2042

    granted
  14. US 11344631

    Promoter for cell-specific gene expression and uses thereof

    Universita' del Piemonte Orientale · Granted May 31, 2022 · Expires May 26, 2042

    granted
  15. US 11345658

    Compounds and compositions comprising the same for treating hypertension or heart failure

    QUANTUM GENOMICS · Granted May 31, 2022 · Expires May 26, 2042

    granted
  16. US 11339393

    Compositions for modulating C9ORF72 expression

    Ionis Pharmaceuticals, Inc. · Granted May 24, 2022 · Expires May 19, 2042

    granted
  17. US 11339198

    Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 24, 2022 · Expires May 19, 2042

    granted
  18. US 11332746

    Compounds and methods for reducing LRRK2 expression

    Ionis Pharmaceuticals, Inc. · Granted May 17, 2022 · Expires May 12, 2042

    granted
  19. US 11324760

    Solid dispersion of dutasteride, method for preparing the solid dispersion, and pharmaceutical composition including the solid dispersion

    KOREA PRIME PHARM CO., LTD. · Granted May 10, 2022 · Expires May 5, 2042

    granted
  20. US 11319536

    Modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted May 3, 2022 · Expires Apr 28, 2042

    granted
  21. US 11317888

    Non-invasive method for pressure measurement

    GE Precision Healthcare LLC · Granted May 3, 2022 · Expires Apr 28, 2042

    granted
  22. US 11312964

    Compositions and methods for modulating growth hormone receptor expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 26, 2022 · Expires Apr 21, 2042

    granted
  23. US 11291659

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Fulcrum Therapeutics, Inc. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  24. US 11293025

    Compositions and methods for modulating Ataxin 3 expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted